Joan Sherman Robbins, 87948 W Tuscany View Rd APT 423, Cottonwood Heights, UT 84047
Joan Robbins Phones & Addresses
948 W Tuscany View Rd APT 423, Midvale, UT 84047
4209 W Benarmine Cir, South Jordan, UT 84009
Sandy, UT
Spring Valley, CA
Murray, UT
Richmond, KY
Mentions for Joan Sherman Robbins
Publications & IP owners
Us Patents
Ribozyme Therapy For The Treatment Of Proliferative Skin And Eye Diseases
US Patent:
6770633, Aug 3, 2004
Filed:
Oct 25, 2000
Appl. No.:
09/696791
Inventors:
Joan M. Robbins - San Diego CA
Richard Tritz - San Diego CA
Richard Tritz - San Diego CA
Assignee:
Immusol, Inc. - San Diego CA
International Classification:
C07H 2104
US Classification:
514 44, 435 6, 435 913, 536 245, 536 232
Abstract:
As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase.
Agents That Regulate Apoptosis
US Patent:
2004024, Dec 9, 2004
Filed:
Jun 25, 2004
Appl. No.:
10/478019
Inventors:
Richard Tritz - San Diego CA, US
Benjamin Keily - San Diego CA, US
Cellia Habita - San Diego CA, US
Joan Robbins - San Diego CA, US
Jack Barber - San Diego CA, US
Benjamin Keily - San Diego CA, US
Cellia Habita - San Diego CA, US
Joan Robbins - San Diego CA, US
Jack Barber - San Diego CA, US
International Classification:
A61K048/00
C07H021/04
C07H021/04
US Classification:
514/044000, 536/023100
Abstract:
The present invention provides genes, nucleic acid sequences, proteins and amino acid sequences that are, involved in the inhibition of apoptosis induction in cells. The invention also provides the RNA correlates of these genes and nucleic acid sequences. Further provided are isolated nucleic acid molecules that interact with the genes, nucleic acid sequences and RNA correlates disclosed herein, such that their inhibitory effect on apoptosis induction is lessened and, therefore, apoptosis induction is facilitated.
Methods And Apparatus For Adeno Associated Virus Purification
US Patent:
2005000, Jan 13, 2005
Filed:
May 11, 2004
Appl. No.:
10/843718
Inventors:
Joan Robbins - San Diego CA, US
Marylou Gibson - Carlsbad CA, US
Marylou Gibson - Carlsbad CA, US
International Classification:
C12N007/02
C12M001/34
C12M001/34
US Classification:
435239000, 435287100
Abstract:
The present invention provides an apparatus for the purification of Adeno-associated virus (AAV) and methods of use including an anion exchange filter unit and a cation exchange capture unit. At one end, the cation exchange capture unit reversibly engages the anion exchange filter unit and when engaged is in fluid communication. The cation exchange capture unit may, at the opposing end, reversibly engage a syringe or apparatus able to provide negative pressure to draw a fluid containing AAV through the anion exchange filter unit then cation exchange capture unit where the AAV is captured. The anion exchange filter unit is disengaged and the purified AAV is eluted from the cation exchange capture unit.
Ribozyme Therapy For The Treatment Of Proliferative Skin And Eye Diseases
US Patent:
2006017, Aug 10, 2006
Filed:
Jan 8, 2004
Appl. No.:
10/753718
Inventors:
Joan Robbins - San Diego CA, US
Richard Tritz - San Diego CA, US
Richard Tritz - San Diego CA, US
International Classification:
A61K 48/00
A61K 38/46
A61K 38/46
US Classification:
514044000, 424094600
Abstract:
As an effective therapy for proliferative skin and eye diseases such as psoriasis and proliferative diabetic retinopathy, this invention provides ribozymes and ribozyme delivery systems which cleave RNA encoding cytokines involved in inflammation, matrix metalloproteinases, a cyclin, a cell-cycle dependent kinase, a growth factor, or a reductase.
Use Of 5,10-Methylene Tetrahydrofolate For The Treatment Of Cancer
US Patent:
2007028, Dec 6, 2007
Filed:
Apr 1, 2005
Appl. No.:
10/594850
Inventors:
Joan Robbins - San Diego CA, US
Mark Cantwell - San Diego CA, US
Mark Cantwell - San Diego CA, US
Assignee:
Adventrx Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 39/395
A61K 31/525
A61K 31/7072
A61K 31/704
A61K 31/4745
A61K 31/337
A61K 31/525
A61K 31/7072
A61K 31/704
A61K 31/4745
A61K 31/337
US Classification:
424145100, 514251000, 514049000, 514269000, 514109000, 514410000, 514449000, 514283000, 514034000, 514492000
Abstract:
The present invention provides novel uses and compositions for 5,10-methylene tetrahydrofolate (“5,10-CH-THFA”) in the treatment of cancer. The present invention is based on the surprising result that 5,10-CH-THFA, while increasing the efficacy of 5-fluoruracil (5-FU) in reducing the rate of tumor growth and increasing survivorship, also reduces the toxicity to the patient of 5-FU. The present invention provides methods and compositions for treating cancer patients that include 5-FU, 5,10-CH-THFA, and one or more additional anticancer drugs. Such methods and compositions can provide increased efficacy and reduced toxicity when compared with current treatment modalities.
Compositions And Methods For The Treatment Of Viral Infections
US Patent:
2008004, Feb 21, 2008
Filed:
Jan 25, 2007
Appl. No.:
11/627062
Inventors:
Joan Robbins - San Diego CA, US
Shani Waninger - Carlsbad CA, US
Shani Waninger - Carlsbad CA, US
Assignee:
Adventrx Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K 31/66
A61P 31/12
A61P 31/12
US Classification:
514120000
Abstract:
The present invention provides compositions and methods for inhibiting the replication of influenza virus by administering thiophosphonoformic acid alone or in combination with a neuraminidase inhibitor, for example, oseltamivir.
Stable Pharmaceutical Compositions Of 5, 10 Methylenetrahydrofolate
US Patent:
2009022, Sep 3, 2009
Filed:
Nov 30, 2006
Appl. No.:
12/095458
Inventors:
Andrew X. Chen - San Diego CA, US
Hongjie Wu - San Diego CA, US
Mark J. Cantwell - San Diego CA, US
Joan M. Robbins - San Diego CA, US
Hongjie Wu - San Diego CA, US
Mark J. Cantwell - San Diego CA, US
Joan M. Robbins - San Diego CA, US
International Classification:
A61K 31/4985
US Classification:
514249
Abstract:
The invention provides a stable lyophilized composition of 5,10 methylenetetrahydrofolate suitable for use in the treatment of cancer and other therapies. The composition comprises 5,10-MTHF in combination with citric acid and ascorbic acid, with the ratio of citric acid to ascorbic acid from about 0.75:1 to about 2.25:1 by weight, and the ratio of total citric acid and ascorbic acid to 5,10-MTHF from about 1.4:1 to about 3.4:1 by weight. Prior to lyophilization, the solution is adjusted to an essentially neutral pH.
Cancer Treatment With Recombinant Vector
US Patent:
2013013, May 23, 2013
Filed:
Mar 29, 2011
Appl. No.:
13/638490
Inventors:
Harry E. Gruber - Rancho Santa Fe CA, US
Douglas J. Jolly - Encinitas CA, US
Omar Perez - San Diego CA, US
Derek G. Ostertag - San Diego CA, US
Joan M. Robbins - San Diego CA, US
Douglas J. Jolly - Encinitas CA, US
Omar Perez - San Diego CA, US
Derek G. Ostertag - San Diego CA, US
Joan M. Robbins - San Diego CA, US
Assignee:
TOCAGEN INC. - San Diego CA
International Classification:
A61K 48/00
A61K 38/22
A61K 38/22
US Classification:
514 129
Abstract:
This disclosure provides modified cytosine deaminases(CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders. It further provides use of such modified CDs with a thymosin-alpha-1 polypeptide in the treatment of disease and disorders.
Isbn (Books And Publications)
Women Changing Therapy : New Assessments, Values And Strategies In Feminist Therapy
Author:
Joan H. Robbins
ISBN #:
0866562397
Women Changing Therapy : New Assessments, Values And Strategies In Feminist Therapy
Author:
Joan H. Robbins
ISBN #:
0866562400
Women Changing Therapy : New Assessments, Values And Strategies In Feminist Therapy
Author:
Joan H. Robbins
ISBN #:
0918393078
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.